Blog
Beam Global (BEEM) Reports Q2 Loss, Lags Revenue Estimates
Beam Global (BEEM) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.14 per share a year ago. These figures are
Gambling.com Group Limited (GAMB) Q2 Earnings and Revenues Beat Estimates
Gambling.com Group Limited (GAMB) came out with quarterly earnings of $0.37 per share, beating the Zacks Consensus Estimate of $0.12 per share. This compares to earnings of $0.2 per share a year
ESS Tech, Inc. (GWH) Reports Q2 Loss, Lags Revenue Estimates
ESS Tech, Inc. (GWH) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to a loss of $1.8 per share a year ago. These figures are
Strattec Security (STRT) Beats Q4 Earnings and Revenue Estimates
Strattec Security (STRT) came out with quarterly earnings of $2.06 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $2.39 per share a year ago. These
Cibus (CBUS) Reports Q2 Loss, Lags Revenue Estimates
Cibus (CBUS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to a loss of $1.14 per share a year ago. These figures are
Dragonfly Energy Holdings Corp. (DFLI) Reports Q2 Loss, Tops Revenue Estimates
Dragonfly Energy Holdings Corp. (DFLI) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $1.29. This compares to a loss of $1.98 per share a year
Compared to Estimates, Applied Materials (AMAT) Q3 Earnings: A Look at Key Metrics
Applied Materials (AMAT) reported $7.3 billion in revenue for the quarter ended July 2025, representing a year-over-year increase of 7.7%. EPS of $2.48 for the same period compares to $2.12 a year
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
Plus Therapeutics (PSTV) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.71 per share a year ago. These
IGC Pharma, Inc. (IGC) Reports Q1 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago. These figures
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks Consensus Estimate of a loss of $6.4. This compares to a loss of $11.2 per share a year ago
Genasys (GNSS) Reports Q3 Loss, Beats Revenue Estimates
Genasys (GNSS) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to a loss of $0.15 per share a year ago. These figures are
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Tops Revenue Estimates
RenovoRx, Inc. (RNXT) came out with a quarterly loss of $0.08 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.1 per share a year ago. These figures are adjusted
Profound Medical (PROF) Reports Q2 Loss, Misses Revenue Estimates
Profound Medical (PROF) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $0.28 per share a year ago. These figures
Evolv Technologies Holdings, Inc. (EVLV) Reports Q2 Loss, Beats Revenue Estimates
Evolv Technologies Holdings, Inc. (EVLV) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.02 per share a year
Guidance Watch: 2 Companies Bullishly Raising Forecasts
The 2025 Q2 earnings cycle is slowly winding down, which has been resilient so far.
For the 457 S&P 500 companies that have reported Q2 results as of August 13th, total earnings are up +11.6% from
P3 Health Partners Inc. (PIII) Reports Q2 Loss, Lags Revenue Estimates
P3 Health Partners Inc. (PIII) came out with a quarterly loss of $6.23 per share versus the Zacks Consensus Estimate of a loss of $3.29. This compares to a loss of $7.5 per share a year ago. These
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago. These
Applied Materials (AMAT) Q3 Earnings and Revenues Beat Estimates
Applied Materials (AMAT) came out with quarterly earnings of $2.48 per share, beating the Zacks Consensus Estimate of $2.34 per share. This compares to earnings of $2.12 per share a year ago. These
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to earnings of $1.52 per share a year ago. These
MacroGenics (MGNX) Reports Q2 Loss, Tops Revenue Estimates
MacroGenics (MGNX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.89 per share a year ago. These figures are
Do Options Traders Know Something About FBIZ Stock We Don't?
Investors in First Business Financial Services, Inc. FBIZ need to pay close attention to the stock based on moves in the options market lately. That is because the Sept. 19, 2025 $55 Call had some
Is the Options Market Predicting a Spike in Hope Bancorp Stock?
Investors in Hope Bancorp, Inc. HOPE need to pay close attention to the stock based on moves in the options market lately. That is because the Sept. 19, 2025 $7.5 Call had some of the highest
Buy or Avoid the Drop in Chipotle & Cava Group's Stock?
Known for generating massive gains for investors, Chipotle CMG and Cava Group CAVA have seen their stocks fall mightily to 52-week lows following their lackluster Q2 results.
This comes as the Zacks
Top Analyst Reports for Merck, Palo Alto & Freeport
Thursday, August 14, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 12 major stocks, including Merck &



